Drug Design for Cardiovascular Therapeutics: Activation of DA1 Receptors
The therapeutic rationale for the utility of drugs to be designed to selectively stimulate DA receptors was that such agents would be selective vasodilators. Because DA receptors were known to mediate vasodilatation and were believed to have a selective distribution in vascular beds such as the renal vasculature, it followed that these drugs might reduce blood pressure or load on the heart without an equivalent decline in kidney blood flow or renal function (Hahn et al., 1982; Goldberg and Raijfer, 1985). Thus, potential therapeutic targets were hypertension, congestive heart failure and conditions associated with reduced renal blood flow and increased renal vascular resistance.
Unable to display preview. Download preview PDF.
- Berkowitz, B. A., Arleth, A. J., Sung, C.-P., Kruse, L. I., DeWolf, W. E. and Ohlstein, E. H. (1988). Effects of the novel dopamine-β-hydroxylase inhibitor, SK&F 102698, on catecholamine and blood pressure in spontaneously hypertensive rats. J. Pharmac. Exp. Ther. (in press)Google Scholar
- Berkowitz, B. A. and Ohlstein, E. H. (1987). Fenoldopam. In A. Scriabine (Ed.), New Cardiovascular Drugs 1987, Raven Press, New York, pp. 237–250Google Scholar
- Foley, J. J. and Sarau, H. M. (1984). Adrenergic binding studies of SK&F 82526 and its enantiomers. Fed. Proc., 43, 555Google Scholar
- Goldberg, L., Kohli, J. P. and Glock, D. (1986). DA1 agonist versus alpha-adrenoceptor antagonist activity of fenoldopam in the dog. Fed. Proc., 45, 195Google Scholar
- Hahn, R. A., Wardell, J. R., Sarau, H. M. and Ridley, P. T. (1982). Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J. Pharmac. Exp. Ther., 233, 305–313Google Scholar
- Lappe, R., Todt, J., and Wendt, R. (1986). Effect of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats. J. Pharmac. Exp. Ther., 236, 187–191Google Scholar
- Molinoff, P., Brimijoin, S. and Axelrod, J. (1972). Induction of dopamine β-hydroxylase and tyrosine hydroxylase in rat hearts and sympathetic ganglia. J. Pharmac. Exp. Ther., 182, 116–129Google Scholar
- Ohlstein, E. H., Kruse, L. I., Ezekiel, M., Sherman, S. S., Erickson, R., DeWolfe, W. E. and Berkowitz, B. A. (1987). Cardiovascular effects of a new potent dopamine β-hydroxylase inhibitor in spontaneously hypertensive rats. J. Pharmac. Exp. Ther., 241, 554–559Google Scholar
- Ohlstein, E. H., Zabko-Potapovich, B. and Berkowitz, B. A. (1984). Studies on vascular dopamine receptors with dopamine receptor agonist: SK&F 82526. J. Pharmac. Exp. Ther., 229, 433–439Google Scholar
- Sole, M. J., Kamble, A. B. and Hussain, M. M. (1977). A possible change in the rate limiting steps for cardiac norepinephrine synthesis in the cardiomyopathetic Syrian hamster. Clin. Res., 41, 814–817Google Scholar
- Szabo, B., Hedler, L. and Starke, K. (1986). Dopamine receptor agonist and alpha-2 adrenoceptor antagonist effects of fenoldopam in rabbits. J. Pharmac. Exp. Ther., 239, 881–886Google Scholar
- Trajkov, T., Berkowitz, B. A. and Spector, S. (1974). Catechol-o-methyltransferase and dopamine β-hydroxylase activity in the blood vessels of hypertensive rats. Blood Vessies, 11, 101–109Google Scholar
- Weiner, N. (1985). In Gilman, A. G., Goodman, L. S., Rall, T. W. and Murad, F. (Eds.) The Pharmacological Basis of Therapeutics, Macmillan., New York, p. 210Google Scholar